RayKnowChina Research Map
Shortlist0

RecruitingHepatocellular carcinomaPhase 2/Phase 3

Registered title, quoted from ClinicalTrials.gov

Camrelizumab Combined With Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma(HCC)

An open trial on hepatocellular carcinoma, registered on ClinicalTrials.gov. Led by Zhongshan Hospital, Fudan University; 1 other hospital on this site is listed as study site.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 2

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorZhongshan Hospital, Fudan University复旦大学附属中山医院ShanghaiHospital page
  2. Study siteHarbin Medical University Cancer Hospital哈尔滨医科大学附属肿瘤医院HarbinHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06796803, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 6

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (6 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. Patients with BCLC stage B (the sum of number of tumors and the maximum diameter of the largest tumor exceeding Up-to-7 criteria) and BCLC stage C without extrahepatic metastasis: ① tumors confined to one lobe (left, right, or middle lobe), or tumors in one lobe are present alongside a single tumor with diameter ≤5 cm or up to three tumors each with diameter ≤3 cm in the remaining lobes; ②No PVTT involving the contralateral liver lobe or reaching the superior mesenteric vein. And no tumor thrombus of the inferior vena cava reaching right atrium

    Inclusion criterion 4

    Child-Pugh ≤7 score

    Inclusion criterion 8

  3. Patients with recurrence following prior radical surgical resection must have undergone the initial surgery at least 5 years prior to study entry

    Inclusion criterion 5

  4. ECOG performance status of 0 or 1

    Inclusion criterion 7

  5. At least one measurable lesion (per RECIST v1.1) untreated lesion

    Inclusion criterion 6

  6. Other active malignant tumor except HCC within 5 years or simultaneously

    Exclusion criterion 2

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; blood tests: counts, liver and kidney function; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06796803, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Signed Informed Consent Form (ICF)
  • Aged ≥18 years and ≤75 years at time of signing ICF
  • Documented diagnosis of HCC confirmed by histology/cytology or clinically
  • Patients with BCLC stage B (the sum of number of tumors and the maximum diameter of the largest tumor exceeding Up-to-7 criteria) and BCLC stage C without extrahepatic metastasis: ① tumors confined to one lobe (left, right, or middle lobe), or tumors in one lobe are present alongside a single tumor with diameter ≤5 cm or up to three tumors each with diameter ≤3 cm in the remaining lobes; ②No PVTT involving the contralateral liver lobe or reaching the superior mesenteric vein. And no tumor thrombus of the inferior vena cava reaching right atrium
  • Patients with recurrence following prior radical surgical resection must have undergone the initial surgery at least 5 years prior to study entry
  • At least one measurable lesion (per RECIST v1.1) untreated lesion
  • ECOG performance status of 0 or 1
  • Child-Pugh ≤7 score
  • Life expectancy ≥12 weeks
  • Adequate organ function
  • No prior anti-tumor systemic therapies for HCC

Exclusion Criteria:

  • Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC
  • Other active malignant tumor except HCC within 5 years or simultaneously
  • Prior locoregional therapy (such as TACE、TAE、HAIC、TARE)
  • There is an absolute contraindication to HAIC
  • History of hepatic encephalopathy
  • Diffuse HCC, intrahepatic tumor burden > 50%
  • PVTT reaching the superior mesenteric vein, and bilateral PVTT are present
  • Clinically significant ascites
  • Prior allogeneic stem cell or solid organ transplantation

Quoted from ClinicalTrials.gov, NCT06796803, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06796803, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06796803